Promentis Pharmaceuticals

What Promentis Pharmaceuticals does

Promentis Pharmaceuticals, Inc. is a privately-held, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Milwaukee, Wisconsin. The company develops orally administered novel small-molecule compounds that activate System xc-, the cystine-glutamate antiporter expressed on astrocytes, with the goal of restoring glutamatergic neurotransmission and addressing oxidative-stress imbalances implicated in neuropsychiatric disorders. Its lead compound, SXC-2023, has completed Phase 1 safety testing in healthy volunteers and is being evaluated in two Phase 2 studies: a monotherapy trial in trichotillomania (a disabling impulse-control disorder affecting over 1% of the US population with no FDA-approved therapy) and an add-on study in obsessive-compulsive disorder (OCD). The broader pipeline includes additional System xc- targeting compounds intended for excoriation disorder, substance-related and addictive disorders, and other CNS conditions linked to glutamatergic dysfunction.

The company was built on intellectual property exclusively licensed from Marquette University, the University of Wisconsin-Milwaukee Research Foundation, and the University of Montana, with scientific founders Dr. David A. Baker and Dr. John Mantsch originating the core System xc- hypothesis. Promentis holds composition-of-matter patents on SXC-2023 in the US and additional jurisdictions and is backed by institutional investors including OrbiMed, F-Prime Capital Partners, and Aisling Capital (co-leads of a $26 million Series C in March 2017), with cumulative equity raised exceeding $31 million. Earlier funding rounds and grants from NIMH and the Michael J. Fox Foundation supported IND-enabling and clinical work. Leadership combines CNS drug-development veterans: CEO/Chairman Klaus Veitinger and Chairman/CEO Daniel Lawton (per conflicting source records) are both former Schwarz Pharma executives, with Tom Beck (F-Prime Capital) as CMO and Chad E. Beyer as SVP of R&D.

Promentis operates a pre-commercial business model with no products approved or generating revenue. Its go-to-market strategy is the standard biopharmaceutical path: complete Phase 2 clinical proof of concept for SXC-2023, pursue FDA regulatory approval, and commercialize through traditional pharmaceutical sales channels (wholesale distributors, specialty pharmacies) targeting patients with trichotillomania and, if successful, expanded OCD and impulse-control disorder populations. The current customer base is defined not by payers but by indication: adult patients with moderate-to-severe trichotillomania who lack any approved therapeutic option, representing the entirety of the addressable market in this orphan-like niche.

Name

Promentis Pharmaceuticals

Legal name

Promentis Pharmaceuticals, Inc.

Website

https://promentispharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Promentis Pharmaceuticals is a privately-held, clinical-stage biopharmaceutical company developing oral small-molecule activators of the System xc- (cystine-glutamate antiporter) platform, with lead compound SXC-2023 in Phase 2 trials for trichotillomania and OCD, addressing CNS disorders with no FDA-approved therapeutics.

Ownership category

akta.pro rank

Product category

Clinical-stage CNS Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Clinical-stage biopharmaceutical
• Neuropsychiatric drug development
• Glutamatergic modulation therapy
• Small molecule CNS therapeutics
• Impulse control disorder treatments

Headquarters

HQ city

Milwaukee

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Revenue: Pre-commercial biopharmaceutical company with no current revenue. Plans to generate revenue through the sale of FDA-approved pharmaceutical products, initially focused on SXC-2023 for trichotillomania treatment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Promentis Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally administered novel small molecule therapies that activate System xc- (cystine-glutamate antiporter) to address glutamatergic imbalance and oxidative stress in neuropsychiatric disorders. Its lead compound, SXC-2023, is being evaluated in Phase 2 clinical trials for trichotillomania, with additional potential applications in OCD, excoriation disorder, substance-related and addictive disorders, and other CNS conditions.

Product overview

Promentis Pharmaceuticals is developing a portfolio of novel oral small molecule compounds targeting System xc-, a unique astrocytic CNS target. The core product is SXC-2023, which activates System xc- to address glutamatergic imbalance and oxidative stress implicated in neuropsychiatric disorders. The company's pipeline includes SXC-2023 as the lead clinical compound in Phase 2 trials for trichotillomania, along with additional proprietary compounds at various stages of development. The technology platform focuses on restoring inhibitory control and executive function through glutamate modulation.

Differentiator

Problem solved

Functional benefit

Products and services

• SXC-2023 SXC-2023 is an orally administered novel small molecule activator of System xc- (cystine-glutamate antiporter) designed to restore glutamatergic neurotransmission and address imbalances in oxidative stress. It has completed Phase 1 single ascending dose and multiple ascending dose safety studies in healthy volunteers and is being assessed in two Phase 2 clinical studies for trichotillomania. The compound is positioned as a potential first-in-class treatment for trichotillomania and is also being explored as add-on therapy in OCD.
• System xc- Targeting Compounds (pipeline portfolio) A portfolio of novel oral compounds engaging System xc-, a CNS target expressed on astrocytes that exchanges extracellular cystine for intracellular glutamate. Includes SXC-2023 and additional proprietary compounds showing promising activity in non-clinical studies, designed to address glutamatergic imbalance and oxidative stress implicated in obsessive-compulsive related disorders, substance-related and addictive disorders, and other CNS conditions.

Quantifiable outcome

• Phase 2A behavioral biomarker study (28 patients) showed significant improvements in impulse control measures
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Marquette UniversitycoreTechnology or IntegrationPromentis obtained an exclusive license from Marquette University to certain intellectual property related to System xc- targeting. Dr. David A. Baker, Co-Founder, is Professor and Associate Chair in the Department of Biomedical Sciences at Marquette University.
• University of Wisconsin-Milwaukee Research FoundationcoreTechnology or IntegrationPromentis obtained an exclusive license from the University of Wisconsin-Milwaukee Research Foundation to certain intellectual property owned by the foundation related to the company's technology platform.
• University of MontanacoreTechnology or IntegrationPromentis obtained an exclusive license from the University of Montana to certain inventions, know-how and intellectual property owned by the university or developed by faculty members or other investigators affiliated with the University of Montana.
• TLC Foundation for Body-Focused Repetitive BehaviorsminorOthersReferenced as an additional resource for trichotillomania information. Dr. Jon Grant serves as Chair of the Scientific Advisory Board of the TLC Foundation.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Compass Pathways: Clinical-stage CNS biopharma developing psychedelic-assisted therapies for treatment-resistant depression and other psychiatric indications, comparable to Promentis as an indication-focused CNS developer in underserved psychiatric populations.
• Neumora Therapeutics: Well-capitalized CNS-focused biopharma with a pipeline addressing depression and other neuropsychiatric conditions, comparable to Promentis in CNS mechanism-driven innovation but operating at substantially larger scale.

Direct peers

• Tonix Pharmaceuticals: Clinical-stage biopharma focused on CNS disorders with a pipeline addressing psychiatric and neurological conditions. Comparable as a small-cap, multi-program CNS developer pursuing niche indications.
• Sage Therapeutics: CNS-focused biopharma developing innovative small-molecule therapies for brain health conditions, with comparable clinical-stage pipeline depth and CNS mechanism-of-action focus.
• Praxis Precision Medicines: Clinical-stage biopharma developing CNS therapies for rare and underserved neurological/psychiatric disorders, with comparable indication-niche strategy and clinical-stage risk profile to Promentis.
• Axsome Therapeutics: Clinical-stage CNS-focused biopharma developing novel therapies for neuropsychiatric disorders, sharing Promentis's small-molecule CNS drug development model and target indication overlap with depression and impulse-control-related conditions.
• Intra-Cellular Therapies: Developer of CNS therapies including Caplyta for schizophrenia — directly comparable to Promentis in CNS indication focus, small-molecule modality, and innovative mechanism targeting underserved psychiatric populations.
• Karuna Therapeutics: CNS-focused clinical-stage biopharma developing xanomeline for psychiatric disorders, sharing Promentis's profile of a venture-backed, mechanism-driven CNS developer pursuing underserved neuropsychiatric indications.

Broad incumbents

• Acadia Pharmaceuticals: Established commercial CNS biopharma with Nuplazid and other CNS products. Comparable as a broader incumbent CNS player that validates the commercial opportunity for CNS-targeted small molecules in rare/underserved psychiatric indications.
• Neurocrine Biosciences: Larger CNS-focused biopharma with multiple approved CNS products including Ingrezza. Serves as a benchmark for the commercial potential of CNS specialty pharmaceutical franchises Promentis aspires to build.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/promentis-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Promentis Pharmaceuticals